Breast cancer treatment and ovarian function. Issue 2 (February 2023)

• Record Type: Journal Article
• Authors: Yildiz, Sule; Bildik, Gamze; Benlioglu, Can; Turan, Volkan; Dilege, Ece; Ozel, Melis; Kim, Samuel; Oktem, Ozgur
• Is Part Of: Reproductive biomedicine online. Volume 46:Issue 2(2023)
• Page Start: 313
• Page End: 331
• Publication Date: 2023-02
• Subjects: Breast cancer -- Chemotherapy-related amenorrhoea -- Fertility preservation -- Ovarian function -- Ovarian reserve; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2022.09.014
• Languages: English
• ISSNs: 1472-6483

Abstract

Abstract: The aim of this study was to provide an update on ovarian function and the mechanisms of gonadal damage after exposure to chemotherapy in breast cancer survivors. The alkylating agents are toxic to both primordial and growing follicles. However, anti-metabolite drugs are more likely to destroy preantral and antral follicles. Younger patients are more likely to have a higher ovarian reserve, and therefore, more likely to retain some residual ovarian function after exposure to gonadotoxic regimens. However, there can be significant variability in ovarian reserve among patients of the same age. Furthermore, patients with critically diminished ovarian reserve may continue to menstruate regularly. Therefore age and menstrual status are not reliable indicators of good ovarian reserve and might give a false sense of security and result in an adverse outcome if the patient is consulted without considering more reliable quantitative markers of ovarian reserve (antral follicle count and anti-Müllerian hormone) and fertility preservation is not pursued. In contrast to well-documented ovarian toxicity of older chemotherapy regimens, data for newer taxane-containing protocols have only accumulated in the last decade and data are still very limited regarding the impact of targeted therapies on ovarian function.